Trial Profile
Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2012
Price :
$35
*
At a glance
- Drugs IPP 204106 (Primary)
- Indications Bladder cancer; Breast cancer; Cancer; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2012 Status changed from recruiting to completed, according to an ImmuPharma media release.
- 06 Dec 2010 New trial record
- 19 Nov 2010 Brief preliminary results have been reported in an ImmuPharma media release.